Is Autolus Therapeutics PLC (AUTL) One of the Fastest-Growing Penny Stocks to Buy Now?

Autolus Therapeutics plc. (NASDAQ:AUTL) is one of the fastest-growing penny stocks to buy now. On November 18 at the Jefferies London Healthcare Conference 2025, CEO Christian Itin reiterated that Autolus Therapeutics PLC (NASDAQ:AUTL) is positioning itself to be a leader in CAR-T therapies. The push comes as the company generated $21.1 million in product revenue in the third quarter, attributed to its CAR-T therapy, AUCATZYL.

In a bid to bolster CAR-T therapy revenues, Autolus plans to launch Ocatzel, its other flagship product for adult acute lymphoblastic leukemia (ALL), with a focus on expanding its market reach and exploring new target areas. The therapy is already available in more than 60 active centers, having generated $51 million in sales in the first nine months of the year.

Plans are underway to explore its potential use in Pediatric ALL and autoimmune diseases to enhance its market target. In addition, it has set its sights on increasing physician adoption and patient awareness to grow market share over the next two years. The company has already established an end-to-end infrastructure to enhance production and supply in the UK and the US.

Autolus Therapeutics plc. (NASDAQ:AUTL) develops and manufactures programmed T cell therapies, primarily CAR T-cell therapies, for the treatment of cancer and autoimmune diseases. It focuses on creating next-generation immunotherapies that are precisely targeted, controlled, and highly active.

While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Stocks Offering High Upside Potential in Data Centers and 10 Best Breakout Stocks to Invest In.

Disclosure: None. This article is originally published at Insider Monkey.